Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice

Purpose This work was undertaken to analyze the efficacy of switchback from aflibercept to ranibizumab in patients with neovascular age-related macular degeneration (nAMD) who had previously switched from ranibizumab to aflibercept. Methods This retrospective double-center study included 45 patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Graefe's archive for clinical and experimental ophthalmology Jg. 254; H. 4; S. 639 - 644
Hauptverfasser:	Despreaux, Raphaelle, Cohen, Salomon Y., Semoun, Oudy, Zambrowski, Olivia, Jung, Camille, Oubraham, Hassiba, Souied, Eric H.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Berlin/Heidelberg Springer Berlin Heidelberg 01.04.2016 Springer Nature B.V
Schlagworte:	Aged Aged, 80 and over Angiogenesis Inhibitors - therapeutic use Drug Substitution Female Fluorescein Angiography Follow-Up Studies Humans Intravitreal Injections Macular degeneration Male Medicine Medicine & Public Health Middle Aged Ophthalmology Ranibizumab - therapeutic use Receptors, Vascular Endothelial Growth Factor - therapeutic use Recombinant Fusion Proteins - therapeutic use Retinal Disorders Retrospective Studies Tomography, Optical Coherence Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - drug effects Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy Wet Macular Degeneration - physiopathology Choroidal neovascularization Switch Age-related macular degeneration Ranibizumab Anti-VEGF Aflibercept Switchback
ISSN:	0721-832X, 1435-702X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Purpose This work was undertaken to analyze the efficacy of switchback from aflibercept to ranibizumab in patients with neovascular age-related macular degeneration (nAMD) who had previously switched from ranibizumab to aflibercept. Methods This retrospective double-center study included 45 patients with nAMD who were previously treated with ranibizumab, then aflibercept, and then ranibizumab again, regardless of the number of intravitreal injections received. The primary outcome was change in best-corrected visual acuity (BCVA) measured on the Early Treatment Diabetic Retinopathy Study ETDRS chart before (T0) and after (T1) the switch, and 3 months after the switchback (T2). Secondary outcomes included changes in central foveal thickness (CFT) measured at T0, T1, and T2, as analyzed on spectral-domain optical coherence tomography (SD-OCT), and the percentage of patients gaining five letters or better. Results Forty-seven eyes of 45 patients were switched back from aflibercept to ranibizumab. The mean BCVA was 67.4 ± 13.4 at T0, 66.7 ± 14.4 at T1, and 68.2 ± 13.9 at T2. BCVA was significantly improved between T1 and T2 ( p = 0.0230), but not between T0 and T1 ( p = 0.5153) or between T0 and T2 ( p = 0.4248). The mean CFT decreased from 317.8 μm ± 89.6 at T0 to 306.9 μm ±68.0 at T1, and to 291.2 μm ± 76.6 at T2. The decrease in CFT was not statistically significant between either T0 and T1 or T1 and T2, but was significant between T0 and T2, when compared before switch and after switchback ( p = 0.0027). However, when considering eyes that received three or more consecutive intravitreal injections of aflibercept before switchback, the statistical significance between T1 and T2 was lost, although a trend towards significance remained ( p = 0.06). Thirteen eyes (27.7 %) gained five letters or more (range, 5–15 letters) after switchback. Conclusions A short-term benefit of switchback from one anti-VEGF agent to another was observed in patients with nAMD who had shown no benefit from the initial switch.
AbstractList	Purpose This work was undertaken to analyze the efficacy of switchback from aflibercept to ranibizumab in patients with neovascular age-related macular degeneration (nAMD) who had previously switched from ranibizumab to aflibercept. Methods This retrospective double-center study included 45 patients with nAMD who were previously treated with ranibizumab, then aflibercept, and then ranibizumab again, regardless of the number of intravitreal injections received. The primary outcome was change in best-corrected visual acuity (BCVA) measured on the Early Treatment Diabetic Retinopathy Study ETDRS chart before (T0) and after (T1) the switch, and 3 months after the switchback (T2). Secondary outcomes included changes in central foveal thickness (CFT) measured at T0, T1, and T2, as analyzed on spectral-domain optical coherence tomography (SD-OCT), and the percentage of patients gaining five letters or better. Results Forty-seven eyes of 45 patients were switched back from aflibercept to ranibizumab. The mean BCVA was 67.4 ± 13.4 at T0, 66.7 ± 14.4 at T1, and 68.2 ± 13.9 at T2. BCVA was significantly improved between T1 and T2 ( p = 0.0230), but not between T0 and T1 ( p = 0.5153) or between T0 and T2 ( p = 0.4248). The mean CFT decreased from 317.8 μm ± 89.6 at T0 to 306.9 μm ±68.0 at T1, and to 291.2 μm ± 76.6 at T2. The decrease in CFT was not statistically significant between either T0 and T1 or T1 and T2, but was significant between T0 and T2, when compared before switch and after switchback ( p = 0.0027). However, when considering eyes that received three or more consecutive intravitreal injections of aflibercept before switchback, the statistical significance between T1 and T2 was lost, although a trend towards significance remained ( p = 0.06). Thirteen eyes (27.7 %) gained five letters or more (range, 5–15 letters) after switchback. Conclusions A short-term benefit of switchback from one anti-VEGF agent to another was observed in patients with nAMD who had shown no benefit from the initial switch. Purpose This work was undertaken to analyze the efficacy of switchback from aflibercept to ranibizumab in patients with neovascular age-related macular degeneration (nAMD) who had previously switched from ranibizumab to aflibercept. Methods This retrospective double-center study included 45 patients with nAMD who were previously treated with ranibizumab, then aflibercept, and then ranibizumab again, regardless of the number of intravitreal injections received. The primary outcome was change in best-corrected visual acuity (BCVA) measured on the Early Treatment Diabetic Retinopathy Study ETDRS chart before (T0) and after (T1) the switch, and 3 months after the switchback (T2). Secondary outcomes included changes in central foveal thickness (CFT) measured at T0, T1, and T2, as analyzed on spectral-domain optical coherence tomography (SD-OCT), and the percentage of patients gaining five letters or better. Results Forty-seven eyes of 45 patients were switched back from aflibercept to ranibizumab. The mean BCVA was 67.4±13.4 at T0, 66.7±14.4 at T1, and 68.2±13.9 at T2. BCVA was significantly improved between T1 and T2 (p=0.0230), but not between T0 and T1 (p=0.5153) or between T0 and T2 (p=0.4248). The mean CFT decreased from 317.8 [mu]m±89.6 at T0 to 306.9 [mu]m ±68.0 at T1, and to 291.2 [mu]m ± 76.6 at T2. The decrease in CFT was not statistically significant between either T0 and T1 or T1 and T2, but was significant between T0 and T2, when compared before switch and after switchback (p=0.0027). However, when considering eyes that received three or more consecutive intravitreal injections of aflibercept before switchback, the statistical significance between T1 and T2 was lost, although a trend towards significance remained (p=0.06). Thirteen eyes (27.7 %) gained five letters or more (range, 5-15 letters) after switchback. Conclusions A short-term benefit of switchback from one anti-VEGF agent to another was observed in patients with nAMD who had shown no benefit from the initial switch. This work was undertaken to analyze the efficacy of switchback from aflibercept to ranibizumab in patients with neovascular age-related macular degeneration (nAMD) who had previously switched from ranibizumab to aflibercept. This retrospective double-center study included 45 patients with nAMD who were previously treated with ranibizumab, then aflibercept, and then ranibizumab again, regardless of the number of intravitreal injections received. The primary outcome was change in best-corrected visual acuity (BCVA) measured on the Early Treatment Diabetic Retinopathy Study ETDRS chart before (T0) and after (T1) the switch, and 3 months after the switchback (T2). Secondary outcomes included changes in central foveal thickness (CFT) measured at T0, T1, and T2, as analyzed on spectral-domain optical coherence tomography (SD-OCT), and the percentage of patients gaining five letters or better. Forty-seven eyes of 45 patients were switched back from aflibercept to ranibizumab. The mean BCVA was 67.4 ± 13.4 at T0, 66.7 ± 14.4 at T1, and 68.2 ± 13.9 at T2. BCVA was significantly improved between T1 and T2 (p = 0.0230), but not between T0 and T1 (p = 0.5153) or between T0 and T2 (p = 0.4248). The mean CFT decreased from 317.8 μm ± 89.6 at T0 to 306.9 μm ±68.0 at T1, and to 291.2 μm ± 76.6 at T2. The decrease in CFT was not statistically significant between either T0 and T1 or T1 and T2, but was significant between T0 and T2, when compared before switch and after switchback (p = 0.0027). However, when considering eyes that received three or more consecutive intravitreal injections of aflibercept before switchback, the statistical significance between T1 and T2 was lost, although a trend towards significance remained (p = 0.06). Thirteen eyes (27.7 %) gained five letters or more (range, 5-15 letters) after switchback. A short-term benefit of switchback from one anti-VEGF agent to another was observed in patients with nAMD who had shown no benefit from the initial switch. PURPOSEThis work was undertaken to analyze the efficacy of switchback from aflibercept to ranibizumab in patients with neovascular age-related macular degeneration (nAMD) who had previously switched from ranibizumab to aflibercept.METHODSThis retrospective double-center study included 45 patients with nAMD who were previously treated with ranibizumab, then aflibercept, and then ranibizumab again, regardless of the number of intravitreal injections received. The primary outcome was change in best-corrected visual acuity (BCVA) measured on the Early Treatment Diabetic Retinopathy Study ETDRS chart before (T0) and after (T1) the switch, and 3 months after the switchback (T2). Secondary outcomes included changes in central foveal thickness (CFT) measured at T0, T1, and T2, as analyzed on spectral-domain optical coherence tomography (SD-OCT), and the percentage of patients gaining five letters or better.RESULTSForty-seven eyes of 45 patients were switched back from aflibercept to ranibizumab. The mean BCVA was 67.4 ± 13.4 at T0, 66.7 ± 14.4 at T1, and 68.2 ± 13.9 at T2. BCVA was significantly improved between T1 and T2 (p = 0.0230), but not between T0 and T1 (p = 0.5153) or between T0 and T2 (p = 0.4248). The mean CFT decreased from 317.8 μm ± 89.6 at T0 to 306.9 μm ±68.0 at T1, and to 291.2 μm ± 76.6 at T2. The decrease in CFT was not statistically significant between either T0 and T1 or T1 and T2, but was significant between T0 and T2, when compared before switch and after switchback (p = 0.0027). However, when considering eyes that received three or more consecutive intravitreal injections of aflibercept before switchback, the statistical significance between T1 and T2 was lost, although a trend towards significance remained (p = 0.06). Thirteen eyes (27.7 %) gained five letters or more (range, 5-15 letters) after switchback.CONCLUSIONSA short-term benefit of switchback from one anti-VEGF agent to another was observed in patients with nAMD who had shown no benefit from the initial switch.
Author	Jung, Camille Cohen, Salomon Y. Semoun, Oudy Souied, Eric H. Despreaux, Raphaelle Zambrowski, Olivia Oubraham, Hassiba
Author_xml	– sequence: 1 givenname: Raphaelle surname: Despreaux fullname: Despreaux, Raphaelle organization: Department of Ophthalmology, Hôpital Intercommunal de Créteil, Faculté de médecine Henri Mondor, Université Paris Est Créteil – sequence: 2 givenname: Salomon Y. surname: Cohen fullname: Cohen, Salomon Y. email: sycsyc75@gmail.com organization: Department of Ophthalmology, Hôpital Intercommunal de Créteil, Faculté de médecine Henri Mondor, Université Paris Est Créteil, Centre Ophtalmologique d’Imagerie et de Laser – sequence: 3 givenname: Oudy surname: Semoun fullname: Semoun, Oudy organization: Department of Ophthalmology, Hôpital Intercommunal de Créteil, Faculté de médecine Henri Mondor, Université Paris Est Créteil – sequence: 4 givenname: Olivia surname: Zambrowski fullname: Zambrowski, Olivia organization: Department of Ophthalmology, Hôpital Intercommunal de Créteil, Faculté de médecine Henri Mondor, Université Paris Est Créteil – sequence: 5 givenname: Camille surname: Jung fullname: Jung, Camille organization: Centre de Recherche Clinique- Centre de Ressources Biologiques, Hôpital Intercommunal de Créteil, Faculté de médecine Henri Mondor, Université Paris Est Créteil – sequence: 6 givenname: Hassiba surname: Oubraham fullname: Oubraham, Hassiba organization: Department of Ophthalmology, Hôpital Intercommunal de Créteil, Faculté de médecine Henri Mondor, Université Paris Est Créteil – sequence: 7 givenname: Eric H. surname: Souied fullname: Souied, Eric H. organization: Department of Ophthalmology, Hôpital Intercommunal de Créteil, Faculté de médecine Henri Mondor, Université Paris Est Créteil, Centre de Recherche Clinique- Centre de Ressources Biologiques, Hôpital Intercommunal de Créteil, Faculté de médecine Henri Mondor, Université Paris Est Créteil
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/26092633$$D View this record in MEDLINE/PubMed
BookMark	eNp9kc9rFTEQx4NU7Gv1D_AiAS-9RPNjN9k9SvEXFDyo0FuYzc6-pmazzyRbsXf_b_N8LUhBTwPD5zPMzPeEHMUlIiHPBX8lODevM-eNMIyLlineNUw8IhvRqJYZLi-PyIYbKVin5OUxOcn5mldcteIJOZaa91IrtSG_Pl8tqbCCaaYJ8xpKpstE8w9f3NUA7hud0jJTmIIfMDncFVoWmiD6wd-uMwzURxpxuYHs1gCJwhZZwgAFRzrDoTfiFiMmKH6Je94FH72DQHcJXPEOn5LHE4SMz-7qKfn67u2X8w_s4tP7j-dvLphreVfYBDAO3Cjei3qVE6hx7DvBB6VlZ2CUg2mdFr1u5ARGY9c3UjuOoMaWO92pU3J2mLtLy_cVc7Gzzw5DgHrCmq0wphVam7ap6MsH6PWypli321ONMlz1plIv7qh1mHG0u-RnSD_t_YMrYA6AS0vOCSfrfPnziJLAByu43UdpD1HaGqXdR2lFNcUD8374_xx5cHJl4xbTX0v_U_oNdi-xeg
CitedBy_id	crossref_primary_10_1007_s00417_020_05000_3 crossref_primary_10_1136_bjophthalmol_2019_314251 crossref_primary_10_1177_1120672119838133 crossref_primary_10_1007_s00417_020_04730_8 crossref_primary_10_1155_2020_9340356 crossref_primary_10_1007_s00417_022_05952_8 crossref_primary_10_2147_OPTH_S371036 crossref_primary_10_1007_s00417_022_05601_0 crossref_primary_10_1016_j_survophthal_2018_02_004 crossref_primary_10_1097_IAE_0000000000004322 crossref_primary_10_1177_25158414211055964 crossref_primary_10_2147_OPTH_S376199 crossref_primary_10_1097_IAE_0000000000001698 crossref_primary_10_1097_IAE_0000000000003418 crossref_primary_10_1007_s40278_016_16672_1 crossref_primary_10_1097_IAE_0000000000001928 crossref_primary_10_1007_s00417_019_04456_2 crossref_primary_10_1007_s10792_017_0695_z
Cites_doi	10.1136/bjophthalmol-2013-304798 10.1136/bjophthalmol-2013-304829 10.1136/bjophthalmol-2013-303344 10.1136/bjophthalmol-2013-303232 10.1097/IAE.0b013e3181a2c1c3 10.1155/2014/273754 10.1136/bjophthalmol-2013-304474 10.1016/j.ajo.2013.03.030 10.1007/s00417-013-2553-7 10.1136/bjophthalmol-2013-304736 10.2147/OPTH.S2094 10.3928/23258160-20140909-03 10.1007/s00417-010-1553-0 10.1136/bjo.2011.203893 10.1097/IAE.0000000000000236 10.1136/bjophthalmol-2011-301236 10.1016/j.ajo.2013.02.017 10.1097/IAE.0b013e31828e8551 10.1016/j.ajo.2013.02.009 10.1007/s00417-014-2589-3 10.2147/OPTH.S50634 10.1038/eye.2014.101
ContentType	Journal Article
Copyright	Springer-Verlag Berlin Heidelberg 2015 Springer-Verlag Berlin Heidelberg 2016
Copyright_xml	– notice: Springer-Verlag Berlin Heidelberg 2015 – notice: Springer-Verlag Berlin Heidelberg 2016
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TK 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7U8 7X8 C1K JXQ
DOI	10.1007/s00417-015-3084-1
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central ProQuest Central UK/Ireland ProQuest Central ProQuest One Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database Proquest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China TOXLINE MEDLINE - Academic Environmental Sciences and Pollution Management Toxline
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) TOXLINE MEDLINE - Academic Environmental Sciences and Pollution Management
DatabaseTitleList	ProQuest One Academic Middle East (New) MEDLINE TOXLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1435-702X
EndPage	644
ExternalDocumentID	3990715961 26092633 10_1007_s00417_015_3084_1
Genre	Research Support, Non-U.S. Gov't Multicenter Study Journal Article
GroupedDBID	--- -53 -5E -5G -BR -EM -Y2 -~C .55 .86 .VR 06C 06D 0R~ 0VY 199 1N0 2.D 203 28- 29I 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3O- 3V. 4.4 406 408 409 40D 40E 53G 5QI 5VS 67Z 6NX 78A 7X7 88E 8AO 8FI 8FJ 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACZOJ ADBBV ADHIR ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI CAG CCPQU COF CSCUP DDRTE DL5 DNIVK DPUIP EBD EBLON EBS EIOEI EJD EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 X7M YLTOR Z45 Z7U Z81 Z82 Z83 Z87 Z8O Z8U Z8V Z8W Z91 ZMTXR ZOVNA ~EX AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ADHKG AEZWR AFDZB AFFHD AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY CGR CUY CVF ECM EIF NPM 7TK 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7U8 7X8 C1K JXQ PUEGO
ID	FETCH-LOGICAL-c508t-faadb073091832c1e6ed9810b36287ad2b75c619642fa76e89426c0ea3d50c683
IEDL.DBID	RSV
ISICitedReferencesCount	21
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000372608100004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0721-832X
IngestDate	Wed Oct 01 14:46:58 EDT 2025 Tue Nov 04 22:12:11 EST 2025 Thu Apr 03 07:00:46 EDT 2025 Sat Nov 29 03:19:52 EST 2025 Tue Nov 18 22:18:34 EST 2025 Fri Feb 21 02:42:35 EST 2025
IsPeerReviewed	true
IsScholarly	true
Issue	4
Keywords	Choroidal neovascularization Switch Age-related macular degeneration Ranibizumab Anti-VEGF Aflibercept Switchback
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c508t-faadb073091832c1e6ed9810b36287ad2b75c619642fa76e89426c0ea3d50c683
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
PMID	26092633
PQID	1774370397
PQPubID	48614
PageCount	6
ParticipantIDs	proquest_miscellaneous_1775166754 proquest_journals_1774370397 pubmed_primary_26092633 crossref_citationtrail_10_1007_s00417_015_3084_1 crossref_primary_10_1007_s00417_015_3084_1 springer_journals_10_1007_s00417_015_3084_1
PublicationCentury	2000
PublicationDate	2016-04-01
PublicationDateYYYYMMDD	2016-04-01
PublicationDate_xml	– month: 04 year: 2016 text: 2016-04-01 day: 01
PublicationDecade	2010
PublicationPlace	Berlin/Heidelberg
PublicationPlace_xml	– name: Berlin/Heidelberg – name: Germany – name: Heidelberg
PublicationSubtitle	Incorporating German Journal of Ophthalmology
PublicationTitle	Graefe's archive for clinical and experimental ophthalmology
PublicationTitleAbbrev	Graefes Arch Clin Exp Ophthalmol
PublicationTitleAlternate	Graefes Arch Clin Exp Ophthalmol
PublicationYear	2016
Publisher	Springer Berlin Heidelberg Springer Nature B.V
Publisher_xml	– name: Springer Berlin Heidelberg – name: Springer Nature B.V
References	CR2 Wykoff, Brown, Maldonado, Croft (CR16) 2014; 98 Bakall, Folk, Boldt, Sohn, Stone, Russell, Mahajan (CR7) 2013; 156 Miura, Iwasaki, Goto (CR13) 2013; 7 Singh, Srivastava, Ehlers, Bedi, Schachat, Kaiser (CR18) 2014; 98 Yonekawa, Andreoli, Miller, Loewenstein, Sobrin, Eliott, Vavvas, Miller, Kim (CR12) 2013; 156 Cho, Shah, Weber, Heier (CR9) 2013; 97 Grewal, Gill, Sarezky, Lyon, Mirza (CR11) 2014; 28 Binder (CR22) 2012; 96 Eghøj, Sørensen (CR23) 2012; 96 Gharbiya, Iannetti, Parisi, De Vico, Mungo, Marenco (CR14) 2014; 2014 Kumar, Marsiglia, Mrejen, Fung, Slakter, Sorenson, Freund (CR20) 2013; 33 Hubschman, Reddy, Schwartz (CR1) 2009; 3 Forooghian, Cukras, Meyerle, Chew, Wong (CR5) 2009; 29 Heussen, Shao, Ouyang, Joussen, Müller (CR17) 2014; 252 Messenger, Campbell, Faridi, Shippey, Bailey, Lauer, Flaxel, Hwang (CR6) 2014; 98 Ferrone, Anwar, Naysan, Chaudhary, Fastenberg, Graham, Deramo (CR21) 2014; 98 Cohen, Souied, Weber, Dupeyron, de Pouvourville, Lievre, Ponthieux (CR4) 2011; 249 Ho, Yeh, Olsen, Bergstrom, Yan, Cribbs, Hubbard (CR8) 2013; 156 Holz, Bandello, Gillies, Mitchell, Osborne, Sheidow, Souied, Figueroa (CR3) 2013; 97 Fassnacht-Riederle, Becker, Graf, Graf, Michels (CR15) 2014; 252 Saito, Kano, Itagaki, Oguchi, Sekiryu (CR19) 2014; 34 Eadie, Gottlieb, Ip, Blodi, Danis, Chandra, Nork, Altaweel, Stern-Hogan (CR10) 2014; 45 3084_CR2 B Bakall (3084_CR7) 2013; 156 PJ Ferrone (3084_CR21) 2014; 98 S-Y Cohen (3084_CR4) 2011; 249 VY Ho (3084_CR8) 2013; 156 F Forooghian (3084_CR5) 2009; 29 H Fassnacht-Riederle (3084_CR15) 2014; 252 S Binder (3084_CR22) 2012; 96 H Cho (3084_CR9) 2013; 97 CC Wykoff (3084_CR16) 2014; 98 JP Hubschman (3084_CR1) 2009; 3 M Miura (3084_CR13) 2013; 7 JA Eadie (3084_CR10) 2014; 45 DS Grewal (3084_CR11) 2014; 28 FG Holz (3084_CR3) 2013; 97 M Saito (3084_CR19) 2014; 34 M Gharbiya (3084_CR14) 2014; 2014 N Kumar (3084_CR20) 2013; 33 MS Eghøj (3084_CR23) 2012; 96 WB Messenger (3084_CR6) 2014; 98 Y Yonekawa (3084_CR12) 2013; 156 RP Singh (3084_CR18) 2014; 98 FM Heussen (3084_CR17) 2014; 252 24518078 - Br J Ophthalmol. 2014 Jul;98(7):951-5 23664153 - Am J Ophthalmol. 2013 Jul;156(1):23-28.e2 25230402 - Ophthalmic Surg Lasers Imaging Retina. 2014 Sep-Oct;45(5):394-7 24836866 - Br J Ophthalmol. 2014 Jun;98 Suppl 1:i22-27 23966764 - Clin Ophthalmol. 2013;7:1591-5 22157632 - Br J Ophthalmol. 2012 Jan;96(1):1-2 23668679 - Am J Ophthalmol. 2013 Jul;156(1):29-35.e2 19668560 - Clin Ophthalmol. 2009;3:155-66 24362854 - Graefes Arch Clin Exp Ophthalmol. 2014 Jun;252(6):909-15 21733918 - Br J Ophthalmol. 2012 Jan;96(1):21-3 23706500 - Am J Ophthalmol. 2013 Jul;156(1):15-22.e1 25077530 - Retina. 2014 Nov;34(11):2192-201 24795334 - Br J Ophthalmol. 2014 Sep;98(9):1205-7 19516114 - Retina. 2009 Jun;29(6):723-31 23549101 - Retina. 2013 Sep;33(8):1605-12 23850682 - Br J Ophthalmol. 2013 Sep;97(9):1161-7 24795335 - Br J Ophthalmol. 2014 Jun;98 Suppl 1:i17-21 24614949 - Graefes Arch Clin Exp Ophthalmol. 2014 Nov;252(11):1705-9 21057805 - Graefes Arch Clin Exp Ophthalmol. 2011 Apr;249(4):521-7 24833178 - Eye (Lond). 2014 Jul;28(7):895-9 23766432 - Br J Ophthalmol. 2013 Aug;97(8):1032-5 24895562 - Biomed Res Int. 2014;2014:273754
References_xml	– volume: 98 start-page: i22 year: 2014 end-page: i27 ident: CR18 article-title: A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis publication-title: Br J Ophthalmol doi: 10.1136/bjophthalmol-2013-304798 – volume: 98 start-page: 1205 year: 2014 end-page: 1207 ident: CR6 article-title: Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration publication-title: Br J Ophthalmol doi: 10.1136/bjophthalmol-2013-304829 – volume: 97 start-page: 1032 year: 2013 end-page: 1035 ident: CR9 article-title: Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab publication-title: Br J Ophthalmol doi: 10.1136/bjophthalmol-2013-303344 – volume: 97 start-page: 1161 year: 2013 end-page: 1167 ident: CR3 article-title: Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme publication-title: Br J Ophthalmol doi: 10.1136/bjophthalmol-2013-303232 – volume: 29 start-page: 723 year: 2009 end-page: 731 ident: CR5 article-title: Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration publication-title: Retina doi: 10.1097/IAE.0b013e3181a2c1c3 – volume: 2014 start-page: 273754 year: 2014 ident: CR14 article-title: Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration publication-title: Biomed Res Int doi: 10.1155/2014/273754 – volume: 98 start-page: i17 year: 2014 end-page: i21 ident: CR21 article-title: Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration publication-title: Br J Ophthalmol doi: 10.1136/bjophthalmol-2013-304474 – volume: 156 start-page: 29 year: 2013 end-page: 35 ident: CR12 article-title: Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2013.03.030 – ident: CR2 – volume: 252 start-page: 909 year: 2014 end-page: 915 ident: CR17 article-title: Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-013-2553-7 – volume: 98 start-page: 951 year: 2014 end-page: 955 ident: CR16 article-title: Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial) publication-title: Br J Ophthalmol doi: 10.1136/bjophthalmol-2013-304736 – volume: 3 start-page: 155 year: 2009 end-page: 166 ident: CR1 article-title: Age-related macular degeneration: current treatments publication-title: Clin Ophthalmol doi: 10.2147/OPTH.S2094 – volume: 45 start-page: 394 year: 2014 end-page: 397 ident: CR10 article-title: Response to aflibercept in patients with persistent exudation despite prior treatment with bevacizumab or ranibizumab for age-related macular degeneration publication-title: Ophthalmic Surg Lasers Imaging Retina doi: 10.3928/23258160-20140909-03 – volume: 249 start-page: 521 year: 2011 end-page: 527 ident: CR4 article-title: Patient characteristics and treatment of neovascular age-related macular degeneration in France: the LUEUR1 observational study publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-010-1553-0 – volume: 96 start-page: 21 year: 2012 end-page: 23 ident: CR23 article-title: Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab publication-title: Br J Ophthalmol doi: 10.1136/bjo.2011.203893 – volume: 34 start-page: 2192 year: 2014 end-page: 2201 ident: CR19 article-title: Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab publication-title: Retina doi: 10.1097/IAE.0000000000000236 – volume: 96 start-page: 1 year: 2012 end-page: 2 ident: CR22 article-title: Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? publication-title: Br J Ophthalmol doi: 10.1136/bjophthalmol-2011-301236 – volume: 156 start-page: 15 year: 2013 end-page: 22 ident: CR7 article-title: Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2013.02.017 – volume: 33 start-page: 1605 year: 2013 end-page: 1612 ident: CR20 article-title: Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration publication-title: Retina doi: 10.1097/IAE.0b013e31828e8551 – volume: 156 start-page: 23 year: 2013 end-page: 28 ident: CR8 article-title: Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2013.02.009 – volume: 252 start-page: 1705 issue: 11 year: 2014 end-page: 1709 ident: CR15 article-title: Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-014-2589-3 – volume: 7 start-page: 1591 year: 2013 end-page: 1595 ident: CR13 article-title: Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis publication-title: Clin Ophthalmol doi: 10.2147/OPTH.S50634 – volume: 28 start-page: 895 year: 2014 end-page: 899 ident: CR11 article-title: Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results publication-title: Eye (Lond) doi: 10.1038/eye.2014.101 – volume: 3 start-page: 155 year: 2009 ident: 3084_CR1 publication-title: Clin Ophthalmol doi: 10.2147/OPTH.S2094 – volume: 7 start-page: 1591 year: 2013 ident: 3084_CR13 publication-title: Clin Ophthalmol doi: 10.2147/OPTH.S50634 – ident: 3084_CR2 – volume: 98 start-page: i22 year: 2014 ident: 3084_CR18 publication-title: Br J Ophthalmol doi: 10.1136/bjophthalmol-2013-304798 – volume: 97 start-page: 1032 year: 2013 ident: 3084_CR9 publication-title: Br J Ophthalmol doi: 10.1136/bjophthalmol-2013-303344 – volume: 96 start-page: 1 year: 2012 ident: 3084_CR22 publication-title: Br J Ophthalmol doi: 10.1136/bjophthalmol-2011-301236 – volume: 2014 start-page: 273754 year: 2014 ident: 3084_CR14 publication-title: Biomed Res Int doi: 10.1155/2014/273754 – volume: 156 start-page: 23 year: 2013 ident: 3084_CR8 publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2013.02.009 – volume: 156 start-page: 29 year: 2013 ident: 3084_CR12 publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2013.03.030 – volume: 252 start-page: 909 year: 2014 ident: 3084_CR17 publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-013-2553-7 – volume: 98 start-page: i17 year: 2014 ident: 3084_CR21 publication-title: Br J Ophthalmol doi: 10.1136/bjophthalmol-2013-304474 – volume: 98 start-page: 1205 year: 2014 ident: 3084_CR6 publication-title: Br J Ophthalmol doi: 10.1136/bjophthalmol-2013-304829 – volume: 249 start-page: 521 year: 2011 ident: 3084_CR4 publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-010-1553-0 – volume: 97 start-page: 1161 year: 2013 ident: 3084_CR3 publication-title: Br J Ophthalmol doi: 10.1136/bjophthalmol-2013-303232 – volume: 98 start-page: 951 year: 2014 ident: 3084_CR16 publication-title: Br J Ophthalmol doi: 10.1136/bjophthalmol-2013-304736 – volume: 45 start-page: 394 year: 2014 ident: 3084_CR10 publication-title: Ophthalmic Surg Lasers Imaging Retina doi: 10.3928/23258160-20140909-03 – volume: 156 start-page: 15 year: 2013 ident: 3084_CR7 publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2013.02.017 – volume: 28 start-page: 895 year: 2014 ident: 3084_CR11 publication-title: Eye (Lond) doi: 10.1038/eye.2014.101 – volume: 34 start-page: 2192 year: 2014 ident: 3084_CR19 publication-title: Retina doi: 10.1097/IAE.0000000000000236 – volume: 96 start-page: 21 year: 2012 ident: 3084_CR23 publication-title: Br J Ophthalmol doi: 10.1136/bjo.2011.203893 – volume: 252 start-page: 1705 issue: 11 year: 2014 ident: 3084_CR15 publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-014-2589-3 – volume: 33 start-page: 1605 year: 2013 ident: 3084_CR20 publication-title: Retina doi: 10.1097/IAE.0b013e31828e8551 – volume: 29 start-page: 723 year: 2009 ident: 3084_CR5 publication-title: Retina doi: 10.1097/IAE.0b013e3181a2c1c3 – reference: 23664153 - Am J Ophthalmol. 2013 Jul;156(1):23-28.e2 – reference: 23766432 - Br J Ophthalmol. 2013 Aug;97(8):1032-5 – reference: 24836866 - Br J Ophthalmol. 2014 Jun;98 Suppl 1:i22-27 – reference: 23706500 - Am J Ophthalmol. 2013 Jul;156(1):15-22.e1 – reference: 25230402 - Ophthalmic Surg Lasers Imaging Retina. 2014 Sep-Oct;45(5):394-7 – reference: 24362854 - Graefes Arch Clin Exp Ophthalmol. 2014 Jun;252(6):909-15 – reference: 23850682 - Br J Ophthalmol. 2013 Sep;97(9):1161-7 – reference: 19668560 - Clin Ophthalmol. 2009;3:155-66 – reference: 23549101 - Retina. 2013 Sep;33(8):1605-12 – reference: 21057805 - Graefes Arch Clin Exp Ophthalmol. 2011 Apr;249(4):521-7 – reference: 24833178 - Eye (Lond). 2014 Jul;28(7):895-9 – reference: 19516114 - Retina. 2009 Jun;29(6):723-31 – reference: 24795334 - Br J Ophthalmol. 2014 Sep;98(9):1205-7 – reference: 24795335 - Br J Ophthalmol. 2014 Jun;98 Suppl 1:i17-21 – reference: 24895562 - Biomed Res Int. 2014;2014:273754 – reference: 24518078 - Br J Ophthalmol. 2014 Jul;98(7):951-5 – reference: 24614949 - Graefes Arch Clin Exp Ophthalmol. 2014 Nov;252(11):1705-9 – reference: 22157632 - Br J Ophthalmol. 2012 Jan;96(1):1-2 – reference: 25077530 - Retina. 2014 Nov;34(11):2192-201 – reference: 21733918 - Br J Ophthalmol. 2012 Jan;96(1):21-3 – reference: 23966764 - Clin Ophthalmol. 2013;7:1591-5 – reference: 23668679 - Am J Ophthalmol. 2013 Jul;156(1):29-35.e2
SSID	ssj0004351
Score	2.2608643
Snippet	Purpose This work was undertaken to analyze the efficacy of switchback from aflibercept to ranibizumab in patients with neovascular age-related macular... This work was undertaken to analyze the efficacy of switchback from aflibercept to ranibizumab in patients with neovascular age-related macular degeneration... Purpose This work was undertaken to analyze the efficacy of switchback from aflibercept to ranibizumab in patients with neovascular age-related macular... PURPOSEThis work was undertaken to analyze the efficacy of switchback from aflibercept to ranibizumab in patients with neovascular age-related macular...
SourceID	proquest pubmed crossref springer
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	639
SubjectTerms	Aged Aged, 80 and over Angiogenesis Inhibitors - therapeutic use Drug Substitution Female Fluorescein Angiography Follow-Up Studies Humans Intravitreal Injections Macular degeneration Male Medicine Medicine & Public Health Middle Aged Ophthalmology Ranibizumab - therapeutic use Receptors, Vascular Endothelial Growth Factor - therapeutic use Recombinant Fusion Proteins - therapeutic use Retinal Disorders Retrospective Studies Tomography, Optical Coherence Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - drug effects Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy Wet Macular Degeneration - physiopathology
SummonAdditionalLinks	– databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7BFqFeeD8CBRmJE8giiRPHOSFArTjAquKlvUXjR0pEm22bLEjc-d-MEycFVfTCNXESKzOe-eyZ-QbgaYraYqqQu1panqnUckRMeVb4GJMTKIYkmi_viuVSrVblfjhw60Ja5WQTB0Nt18afkb9ICKcIUs-yeHl8wn3XKB9dDS00LsOWZyrLFrD1ene5_-GsMlIMDRg9CRgn3V1Ncc14pBFNfNplzkWsMp787ZnOwc1zodLBA-1d_9-534BrAXuyV6Oy3IRLrr0FV9-H6Ppt-PXxK4Fx7o01o1345rDv2Lpm3Y-GRKvRfGO-GIVhPeSk-HwY1q8ZObtGNz83R6hZ07LWzdmtjGwVH4plnGVHOF6z7mBguvYK4cdPpZlsqte6A5_3dj-9ectDmwZuCN31vEa02luK0psHkzjpbKmSWJNvVAXaVBe5kZ74K62xkE6VhApM7FDYPDZSibuwaNetuw9Mm4IgH6a5IiQpS6lRSGnrpNYoMyPjCOJJRJUJHOa-lcZhNbMvD1KtSKqVl2qVRPBsfuR4JPC4aPDOJMAqrOWuOpNeBE_m27QKfWgF6a9uhjF5ImnzlUVwb9SX-Wu0YyxTKUQEzycF-uPl_5rKg4un8hC2CbrJMYdoBxb96cY9givme990p4_DMvgNLIsOpw priority: 102 providerName: ProQuest
Title	Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice
URI	https://link.springer.com/article/10.1007/s00417-015-3084-1 https://www.ncbi.nlm.nih.gov/pubmed/26092633 https://www.proquest.com/docview/1774370397 https://www.proquest.com/docview/1775166754
Volume	254
WOSCitedRecordID	wos000372608100004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1435-702X dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0004351 issn: 0721-832X databaseCode: 7X7 dateStart: 19971001 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1435-702X dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0004351 issn: 0721-832X databaseCode: BENPR dateStart: 19971001 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1435-702X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004351 issn: 0721-832X databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9UwEB5Bi1Av7EugPBmJE8hSEieOcwTUigM8VS1U7xaNl5SINq9q8kDizv9m7CyACkhwySGZJNZ4lm80iwGepagtpgq5q6XlmUotR8SUZ4XPMTmBIhTRHL8tlku1WpUHYx93N1W7TynJYKnnZjc_GsqXSeZcxCrjFPJsk7dTXhsPj45_NEOKcOain_vFSVxXUyrzd5_41RldQpiXsqPB6ezf_K_l3oIbI8ZkLwehuA1XXHsHrr8bs-h34dvRRwLd3BtlRtH25rTv2Lpm3ZeGtlCj-cR80wnDOtSe-LoX1q8ZObVGN183Z6hZ07LWzVWsjGwSD00xzrIzHO5ZdxImWvuN9_RTCyab-rLuwYf9vfev3_DxOAZuCMX1vEa02luE0psBkzjpLLE_1uQDVYE21UVupB_wldZYSKdK8v4mdihsHhupxH3YatetewhMm4KgHaa5IsQoS6lRSGnrpNYoMyPjCOJpXyozzir3R2acVvOU5cDeithbefZWSQTP51fOh0EdfyPenTa7GnW2qxJCwoIMYFlE8HR-TNrmUyhIXN0EmjyRFGRlETwYhGT-G0WGZSqFiODFJBE_ffxPS3n0T9SPYYcQmxxKh3Zhq7_YuCdwzXzum-5iAVeLVRGuagHbr_aWB4eLoBzfAf2CBfk
linkProvider	Springer Nature
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgoAL70eggJHgArJI7MRJDgghoGrV7QqJgvYW_Eob0WbLJksFd_4Ov5Gx8yioorceuCaOYzmf55H5ZgbgCZPKSJZJakthaJwxQ6WUjMapizFZLrkn0XyapNNpNpvl71fg15AL42iVg0z0gtrMtftH_iJCO4UjPPP01eFX6rpGuejq0EKjg8WW_X6ELlvzcvMtft-njK2_23mzQfuuAlSjMdLSUkqjHLBzh2YdWWFNnkWhQlGepdIwlSZauDpVrJSpsFmOSkyHVnKThFpkHOc9B-dRjqeOQpbO0uM8TO7bPbqSYxTnng1R1LArWho5kmdCeZjFNPpbD54wbk8EZr2-W7_6v-3UNbjSW9bkdXcUrsOKrW_Axe2eO3ATfn7YQ1eDOlVEFrZZ7rcNmZekOaoQuErqL8Sl2hBZesaNY_uQdk5QlVeq-rE8kIpUNantyN0lKImpTwWyhhzI7pqxu76Ot4O7Gz8knpIhG-0WfDyTTbgNq_W8tneBKJ2iQStZkqGdLHKhJBfClFGppIi1CAMIB0gUuq_Q7hqF7BdjbWmPogJRVDgUFVEAz8ZHDrvyJKcNXhsAU_SSqimO0RLA4_E2yhgXOJK4q0s_JokEupZxAHc6fI5vQ384Z4LzAJ4PgP1j8n8t5d7pS3kElzZ2tifFZHO6dR8uo5EqOrbUGqy2i6V9ABf0t7ZqFg_9ASTw-axx_BtXymjK
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VLaq48H4EChgJLiCriZ04yQEhoF1RtaxWvLS34FfaiDZbNlkquPOn-HWM8yqoorceuCaOYzmf55H5ZgbgMZPKSJZIanNhaJgwQ6WUjIaxizFZLnlDovm0G08myWyWTlfgV58L42iVvUxsBLWZa_ePfCNAO4UjPNN4I-9oEdPN8Yujr9R1kHKR1r6dRguRHfv9GN236vn2Jn7rJ4yNtz68fkO7DgNUo2FS01xKoxzIU4dsHVhhTZoEvkKxnsTSMBVHWriaVSyXsbBJigpN-1ZyE_laJBznvQCrMRoZ0QhWX21Npu9OsjJ50_zRFSCjOPusj6n6bQnTwFE-I8r9JKTB31rxlKl7KkzbaL_xlf95367C5c7mJi_bQ3INVmx5HdbedqyCG_Dz_T46IdQpKbKw1fKgrsg8J9VxgZBWUn8hLgmHyLzh4jgeEKnnBJV8oYofy0OpSFGS0g6sXoIymjZJQtaQQ9leM3avqfDtDoIb36ekkj5P7SZ8PJdNuAWjcl7aO0CUjtHUlSxK0IIWqVCSC2HyIFdShFr4Hvg9PDLd1W53LUQOsqHqdIOoDBGVOURlgQdPh0eO2sIlZw1e78GTdTKsyk6Q48Gj4TZKHxdSkriry2ZMFAh0OkMPbrdYHd6GnnLKBOcePOvB-8fk_1rK3bOX8hDWEL7Z7vZk5x5cQutVtDSqdRjVi6W9Dxf1t7qoFg-600jg83kD-Tc13nLq
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Short-term+results+of+switchback+from+aflibercept+to+ranibizumab+in+neovascular+age-related+macular+degeneration+in+clinical+practice&rft.jtitle=Graefe%27s+archive+for+clinical+and+experimental+ophthalmology&rft.au=Despreaux%2C+Raphaelle&rft.au=Cohen%2C+Salomon+Y&rft.au=Semoun%2C+Oudy&rft.au=Zambrowski%2C+Olivia&rft.date=2016-04-01&rft.eissn=1435-702X&rft.volume=254&rft.issue=4&rft.spage=639&rft.epage=644&rft_id=info:doi/10.1007%2Fs00417-015-3084-1&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0721-832X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0721-832X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0721-832X&client=summon